Overview

Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia

Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of celecoxib as add-on therapy to risperidone versus risperidone alone in patients with schizophrenia
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Celecoxib
Risperidone